Antibody,
Biopharmaceutical,
Residence Inn by Marriott,
Nature,
Surface plasmon resonance,
LSA,
SPR,
Marketing,
Partnership,
Cell,
NGS,
Therapy,
Drug discovery,
Pharmaceutical industry The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada.
Key Points:
- The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada.
- The symposium will bring together all levels of scientific leadership from the biotech and pharma communities.
- "We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery," said Steve Lavezoli, Vice President of Biologics at Curia.
- Coming to the Pacific Northwest is an opportunity to create a deeper understanding of the technology in pharma and biotechs in this region.”
Retrieved on:
Friday, February 23, 2024
ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.
Key Points:
- ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.
- Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.
- “This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb.
- “Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts.
ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group.
Key Points:
- ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group.
- “Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia.
- “Congratulations to our 2024 CDMO Leadership Award winners.
- The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”
Retrieved on:
Friday, December 15, 2023
ALBANY, N.Y., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced that Gerald Auer has been appointed as chief financial officer.
Key Points:
- ALBANY, N.Y., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced that Gerald Auer has been appointed as chief financial officer.
- “I am delighted to welcome Gerald to Curia as we head into the new year," said Curia CEO Philip Macnabb.
- “Curia is a dynamic company in the CDMO space with an inspirational mission to improve patients’ lives,” said Auer.
- “I look forward to collaborating with the talented team at Curia to help drive that mission for our customers and their patients.”
Retrieved on:
Tuesday, December 5, 2023
ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook.
Key Points:
- ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook.
- The full list can be viewed in the November 2023 edition of the India Pharma Outlook magazine .
- This recognition acknowledges the contributions of Curia’s Aurangabad and Hyderabad sites.
- These sites also house Curia’s quality control center and Global Shared Services (GSS) center, which support the company’s global organization, enabling process standardization and scalability.
Retrieved on:
Wednesday, September 13, 2023
Vaccine,
Research and development,
Therapy,
RNA,
Messenger,
Trial of the century,
CGMP,
FDA,
IND,
Replicate,
Pharmaceutical industry,
Fine chemical Curia conducted process development, scale-up and cGMP manufacture of srRNA RBI-4000 drug substance.
Key Points:
- Curia conducted process development, scale-up and cGMP manufacture of srRNA RBI-4000 drug substance.
- At approximately 10,000 bases, this srRNA is significantly larger than a conventional linear mRNA and has been historically difficult to manufacture at the scales required for clinical development.
- “Curia is proud to be a pioneer in manufacturing this new class of srRNA technology by delivering RBI-4000 srRNA drug substance to our partner Replicate in support of their Phase 1 clinical trial,” said Christopher Conway, President, Research & Development, Curia.
- The advancement also opens the door for further RNA innovation for use in vaccines and therapeutics with fewer constraints on molecule size.
ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).
Key Points:
- ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).
- The arrangement expands Curia’s mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers.
- “Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities,” said Christopher Conway, President of R&D, Curia.
- Touchlight’s enzymatic DNA is produced with a cell-free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.
ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.
Key Points:
- ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.
- “Curia has built its reputation by offering a best-in-class customer ownership and service experience.
- The company surveys clients to gauge their overall satisfaction and ensure that it is upholding the highest standards,” said Unmesh Lal, director, Healthcare & Life Sciences, Frost & Sullivan.
- Each year, Frost & Sullivan employs a rigorous evaluation, measuring business and customer impact, to identify companies that consistently innovate to meet their customers’ needs while navigating new challenges and opportunities.
Immortalised cell line,
GMP,
Sigma-Aldrich,
Workflow,
CHO,
Antibody,
Glutamine,
Merck,
GS,
Hamster,
Fine chemical,
Vaccine Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.
Key Points:
- Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.
- The glutamine synthetase GS knockout (GS-/-) cell line of the CHOZN platform is specially designed to help streamline selection, identification and scale-up of high-producing clones ideal for GMP manufacturing of recombinant protein drugs.
- “The CHOZN GS-/- cell line platform adds a widely accepted and commercially viable cell line to our capabilities.
- The addition of the CHOZN platform strengthens Curia’s offerings as a complement to its existing proprietary CHO cell line, providing customers with a highly versatile and broadly applicable solution.
ALBANY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally.
Key Points:
- ALBANY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally.
- Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs, and provides advantages compared with traditional batch processing.
- “Innovation in drug development and production calls for safety at high speed,” said Christopher Conway, president, Research & Development, Curia.
- “Collaborating with an innovation-focused company like Curia will help drive advancements in the chemical-processing industry,” said Alessandra Vizza, business director, Corning Advanced-Flow Reactors.
